Market Overview

UPDATE: Barrington Research Initiates TranS1 at Outperform on Growth Outlook

Related TSON
UPDATE: Piper Jaffray Lowers PT on TranS1 Following Updated Projections
Stocks Hitting 52-Week Lows

Barrington Research initiated coverage on TranS1 (NASDAQ: TSON) with an Outperform rating and a $4 price target.

Barrington Research said, "We estimate that the minimally invasive spinal fusion market is less than 30% of the total market and over the next few years, we expect the percentage of minimally invasive procedures to approach 60%. We estimate the potential lumbar spinal fusion market is well in excess of $1 billion. We believe TSON has the least invasive approach for the treatment of S1/L5/L4 and in our opinion, TSON will be a market leader of this segment as the company convinces the masses, doctor by doctor."

TranS1 closed at $2.42 on Friday.

Latest Ratings for TSON

DateFirmActionFromTo
Mar 2013Piper JaffrayMaintainsOverweight
Feb 2013JMP SecuritiesInitiates Coverage onMarket Outperform
Dec 2012Barrington ResearchInitiates Coverage onOutperform

View More Analyst Ratings for TSON
View the Latest Analyst Ratings

Posted-In: Barrington ResearchAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (TSON)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters